Z
Zhenggang Ren
Researcher at Fudan University
Publications - 184
Citations - 5994
Zhenggang Ren is an academic researcher from Fudan University. The author has contributed to research in topics: Hepatocellular carcinoma & Medicine. The author has an hindex of 33, co-authored 151 publications receiving 3444 citations. Previous affiliations of Zhenggang Ren include Chinese Ministry of Education.
Papers
More filters
Journal ArticleDOI
Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2-3 study.
Zhenggang Ren,Jianming Xu,Yuxian Bai,Aibing Xu,Shundong Cang,Chengyou Du,Qiu Li,Yinying Lu,Yajin Chen,Yabing Guo,Zhendong Chen,Baorui Liu,Weidong Jia,Jian Wu,Junye Wang,Guoliang Shao,Bixiang Zhang,Yunfeng Shan,Zhiqiang Meng,Jianbing Wu,Shanzhi Gu,Wei Yang,Chao Liu,Xuetao Shi,Zhenyuan Gao,Tao Yin,Jiuwei Cui,Ming Huang,Baocai Xing,Yilei Mao,Gao-Jun Teng,Yanru Qin,Jinhai Wang,Feng Xia,Guowen Yin,Yong Yang,Mingxia Chen,Yan Wang,Hui Zhou,Jia Fan +39 more
TL;DR: The phase 2-3 ORIENT-32 study as discussed by the authors compared sintilimab (a PD-1 inhibitor) plus IBI305, a bevacizumab biosimilar, versus sorafenib as a first-line treatment for unresectable HBV-associated hepatocellular carcinoma.
Journal ArticleDOI
Camrelizumab in patients with previously treated advanced hepatocellular carcinoma: a multicentre, open-label, parallel-group, randomised, phase 2 trial
Shukui Qin,Zhenggang Ren,Zhiqiang Meng,Zhendong Chen,Xiaoli Chai,Jianping Xiong,Yuxian Bai,Lin Yang,Hong Zhu,Weijia Fang,Xiaoyan Lin,Xiaoming Chen,Enxiao Li,Linna Wang,Chunxia Chen,Jianjun Zou +15 more
TL;DR: Camrelizumab showed antitumour activity in pretreated Chinese patients with advanced hepatocellular carcinoma, with manageable toxicities, and might represent a new treatment option for these patients.
Journal ArticleDOI
Camrelizumab in Combination with Apatinib in Patients with Advanced Hepatocellular Carcinoma (RESCUE): A Nonrandomized, Open-label, Phase II Trial.
Jian-Ming Xu,Jie Shen,Shanzhi Gu,Yun Zhang,Lihua Wu,Jian Wu,Guoliang Shao,Yanqiao Zhang,Li Xu,Tao Yin,Jingfeng Liu,Zhenggang Ren,Jianping Xiong,Xianhai Mao,L Zhang,Jiayin Yang,Le-Qun Li,Xiaoming Chen,Zhiming Wang,Kangsheng Gu,Xi Chen,Zhanyu Pan,Kuansheng Ma,Xinmin Zhou,Zujiang Yu,Enxiao Li,Guowen Yin,Xiao Zhang,Shuni Wang,Quan Ren Wang +29 more
TL;DR: Camrelizumab combined with apatinib showed promising efficacy and manageable safety in patients with advanced HCC in both the first-line and second-line setting, and might represent a novel treatment option for these patients.
Journal ArticleDOI
2019 Chinese clinical guidelines for the management of hepatocellular carcinoma: updates and insights
TL;DR: The China liver cancer (CNLC) staging system, proposed in the 2017 guidelines, continues to be the standard model for patient classification, with subsequent modifications and updates being made in treatment allocations.
Journal ArticleDOI
Combined Hepatocellular Carcinoma and Cholangiocarcinoma: Clinical Features, Treatment Modalities, and Prognosis
Xin Yin,Bo-Heng Zhang,Shuang-Jian Qiu,Zhenggang Ren,Jian Zhou,Xiao-Hong Chen,Ying Zhou,Jia Fan +7 more
TL;DR: cHCC-CC has biological behavior and prognosis that are intermediate between HCC and ICC and radical liver resection can provide a better outcome for this uncommon malignancy.